CareDx Acquires Naveris to Expand Into Methylation-Based Oncology Diagnostics
CDNA•CareDx has acquired Naveris for an undisclosed sum, gaining access to its proprietary methylation-based liquid biopsy assays for specialty oncology diagnostics. This marks CareDx’s first expansion beyond transplant monitoring, positioning it in a high-growth cancer detection market and diversifying its diagnostics revenue stream.
1. Acquisition Details
CareDx announced it will acquire Naveris, a developer of methylation-based liquid biopsy tests for early cancer detection, in a transaction closed for an undisclosed sum. The deal grants CareDx access to Naveris’ proprietary assay platform and research pipeline in specialty oncology.
2. Strategic Rationale
This acquisition represents CareDx’s first foray beyond transplant diagnostics, leveraging Naveris’ expertise to enter a specialty oncology segment projected to grow rapidly. By integrating Naveris’ technology, CareDx aims to diversify revenue sources and strengthen its positioning in the broader molecular diagnostics market.
